Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2Recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 2NETWORK 1INDUSTRY 1

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Breast Neoplasms 13110Neoplasms 10462Carcinoma, Non-Small-Cell Lung 6857Prostatic Neoplasms 6258Colorectal Neoplasms 5925Lung Neoplasms 5091Multiple Myeloma 3568Pancreatic Neoplasms 3552Leukemia, Myeloid, Acute 3503Neoplasm Metastasis 3499Carcinoma, Hepatocellular 3264Ovarian Neoplasms 3160Melanoma 3134Stomach Neoplasms 3051Lymphoma 2981Head and Neck Neoplasms 2595Recurrence 2548Precursor Cell Lymphoblastic Leukemia-Lymphoma 2496Leukemia 2360Colonic Neoplasms 2326Brain Neoplasms 2306Lymphoma, Non-Hodgkin 2265Rectal Neoplasms 2186Uterine Cervical Neoplasms 2182Glioblastoma 2010Leukemia, Lymphocytic, Chronic, B-Cell 1992Carcinoma, Renal Cell 1910Squamous Cell Carcinoma of Head and Neck 1875Lymphoma, Follicular 1847Esophageal Neoplasms 1797

Interventions

Azacitidine 2selinexor 1eprenetapopt 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
MDS × Clear all
NCT03745716 2025-03-18

APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)

Aprea Therapeutics

Phase 3 Completed
154 enrolled 10 charts

MDS

NCT06664970 2024-10-30

A Multicenter Study on the Treatment of MDS/MPN Overlap Syndrome With AZA or Rux Combined With Selinexor

Peking Union Medical College Hospital

Phase 2 Enrolling by invitation
39 enrolled

MDS

NCT06267898 2024-02-20

Non Interventional Study on Iron Toxicity After First Allo-transplant in MDS/CMML

European Society for Blood and Marrow Transplantation

Completed
222 enrolled

MDS

NCT05009537 2021-08-17

CARTOGEN

University Hospital, Brest

Recruiting
200 enrolled
Other neoplasm

MDS

Data powered by HemOnc (CC BY 4.0) Colophon âš¡